Phase I Trial of Endoxifen Gel versus Placebo in Women Undergoing Breast Surgery

Status: Active

Description

This randomized phase I trial studies the side effects and best dose of Z-endoxifen hydrochloride in treating participants who are undergoing breast surgery. Z-endoxifen hydrochloride may treat or reduce the risk of breast cancer.

Eligibility Criteria

Inclusion Criteria

  • Women scheduled for unilateral or bilateral mastectomy for breast cancer therapy, pathology confirmed stage 0-III (including ductal carcinoma in situ), or prophylaxis (BRCA1/2 mutation carriers, women with strong family history or lobular carcinoma in situ or other conditions where prophylactic mastectomy has been elected)
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
  • Total bilirubin < 1.5 X upper limit of normal (ULN) (in women with prior documented bilirubin elevations consistent with Gilbert’s syndrome, total bilirubin up to 3 X ULN will be allowed)
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) < 2.5 X ULN
  • Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X ULN
  • Creatinine < 2 X ULN
  • Alkaline phosphatase < 2.5 X ULN
  • Blood urea nitrogen < 2 X ULN
  • Ability to understand and the willingness to sign a written informed consent document
  • Willingness and ability to schedule mastectomy 21-28 days following start of study agent; women with breast implants may participate
  • Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of study agent dosing
  • Negative urine or serum pregnancy test result, for participants of child bearing potential; female of child-bearing potential is any woman (regardless of sexual orientation, whether she has undergone a tubal ligation, or remains celibate by choice) who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; AND has had a menstrual period at any time in the preceding 12 consecutive months)
  • Women of child-bearing potential and their male partners must agree to use effective forms of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately

Exclusion Criteria

  • The presence of gross skin invasion/ulceration by the breast cancer, or inflammatory changes with skin edema AND erythema; Note: Paget’s disease is permitted
  • Women receiving a “nipple delay” procedure prior to mastectomy
  • Women with skin diseases (psoriasis, eczema)
  • A history of thromboembolic disorder
  • Participants may not have received any other investigational agents in the previous 3 months
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen
  • Taken tamoxifen or other selective estrogen/progesterone receptor modulators (SERMs/SPRMs) within two years prior to entering study or been required to discontinue SERM therapy due to thromboembolic or uterine toxicity
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • History of prior breast cancer-specific therapy within the previous 2 years (chemotherapy, radiation, anti-HER2 agents, endocrine agents, everolimus, CDK4-6 inhibitors); previous unilateral radiation of the contralateral side in women scheduled for mastectomy is allowed; study gel will be applied to both breasts
  • History of prior mastectomy
  • Pregnant or breastfeeding
  • Patients receiving neoadjuvant chemotherapy with curative intent
  • Current users of other topical medications on the breast skin must be willing and able to discontinue use for the duration of participation; body lotion and other non-medicinal topical compounds may be applied > 4 hours after study gel application

Locations & Contacts

California

Los Angeles
Cedars Sinai Medical Center
Status: Active
Contact: Scott R. Karlan
Phone: 310-423-9331
Email: KarlanS@cshs.org

Illinois

Chicago
Northwestern University
Status: Active
Contact: Seema Ahsan Khan
Phone: 312-472-0585
Email: skhan@nm.org

New York

New York
Memorial Sloan Kettering Cancer Center
Status: Approved
Contact: Melissa L. Pilewskie
Phone: 646-888-4590
Email: pilewskm@mskcc.org

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To establish the dermal tolerability and safety of Z-endoxifen hydrochloride (endoxifen) (ENX) gel administered topically to both breasts at two doses: 10 mg daily (5 mg per breast) and 20 mg daily (10 mg per breast) in comparison to vehicle placebo gel, using objective assessments based on Common Terminology Criteria for Adverse Events (CTCAE) criteria.

SECONDARY OBJECTIVES:

I. To measure the breast tissue concentrations of (E) and (Z) isomers of N-desmethyl-4-hydroxytamoxifen (ENX) and 4-hydroxytamoxifen (4-OHT) at each dose (10 mg per day and 20 mg per day).

II. To measure the plasma concentrations of (E) and (Z) isomers ENX and 4-OHT at each dose (10 mg per day and 20 mg per day).

III. To measure plasma hormone levels for steroid hormones (estradiol, progesterone, dehydroepiandrostenedione [DHEA], androstenedione, testosterone) in comparison to vehicle placebo gel.

IV. To measure serum estrogenic response to topical ENX gel therapy in comparison to vehicle placebo gel (sex hormone binding globulin and insulin-like growth factor [IGF] pathway proteins).

V. To assess changes in coagulation parameters (factor VIII, factor IX, vWF, protein S) in response to ENX gel therapy in comparison to vehicle placebo gel.

VI. Using pre- and post-therapy tissue samples, to explore the potential therapeutic effects of the two doses of ENX gel in comparison to vehicle placebo gel: a) by IHC, Ki67 labelling (for cell proliferation), estrogen receptor (ER), progesterone receptor (PR) expression (for estrogen blockade); b) by expression of a panel of genes reported to change with ENX exposure (using nanostring assays).

VII. Bank germline deoxyribonucleic acid (DNA) for future pooled analyses of polymorphisms in tamoxifen metabolizing enzymes in comparison to vehicle placebo gel.

VIII. To assess symptoms related to use of endoxifen gel in comparison to vehicle placebo gel, as assessed by the Breast Cancer Prevention Trial (BCPT) Eight Symptom Scale (BESS) questionnaire.

OUTLINE: Participants are randomized into 1 of 2 cohorts.

COHORT I: Participants apply Z-endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.

COHORT II: Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.

After completion of study treatment, participants are followed up at 60 days.

Trial Phase & Type

Trial Phase

Phase I

Trial Type

Treatment

Lead Organization

Lead Organization
Northwestern University

Principal Investigator
Seema Ahsan Khan

Trial IDs

Primary ID NCI2017-09-01
Secondary IDs NWU2017-09-01, NCI-2017-01921, N01-CN-2012-00035
Clinicaltrials.gov ID NCT03317405